CommercialPrior AuthMedium impact
08.00.34v, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology +1 more·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.34v updates medical necessity criteria for intravenous Infliximab and related biosimilars. This recent change (1 month old) affects coverage determination and prior authorization requirements for this biologic therapy. The billing team must verify current medical necessity documentation standards and update prior authorization processes accordingly.
Action Required
By April 21, 2025 (effective immediately): Billing team and prior authorization staff must review the updated medical necessity criteria in policy 08.00.34v for intravenous Infliximab and biosimilars. Update prior authorization templates and workflows to reflect new criteria. Coordinate with providers to ensure documentation submitted with claims meets updated medical necessity standards. Train billing staff on the new requirements. Failure to apply updated criteria may result in claim denials or delays. Reference the full policy at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-34v for specific medical necessity details.